2-1250 Waverley Street
MB R3T 6C6
Canada - Map
|Full Time Employees:||N/A|
Medicure Inc., a biopharmaceutical company, researches, develops, and commercializes human therapeutics in Canada, the United States, and Barbados. The company markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It is also developing Tardoxal, which is in Phase IIa clinical trial for the treatment of tardive dyskinesia/neurological indications; and Transdermal AGGRASTAT that is in a preclinical stage for acute cardiology. In addition, the company offers novel therapeutics comprising a series of small molecule dual acting anticoagulant/antiplatelet compounds to treat venous and arterial thrombosis. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.
|Dr. Albert D. Friesen Ph.D.,
Founder, Chairman and Chief Exec. Officer
|Mr. Dawson J. Reimer MAFS,
Pres and Chief Operating Officer
|Mr. James Kinley C.A.,
Chief Financial Officer and Sec.
|Dr. George R. Thomas M.Pharm, Ph.D.,
Director of R&D
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|